Related Experiment Video
Updated: May 31, 2026
05:52
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
Risk factors for tardive dyskinesia
S Datta1, T P Subhalakshmi, L Jeyaseelan
1Sunil Datta, MD, Department of Psychiatry, Department of Psychiatry, Christian Medical College, Vellore - 632 002.
Indian Journal of Psychiatry
|July 12, 2011
Summary
Persistent tardive dyskinesia (TD) affects over a quarter of patients on antipsychotics long-term. Higher doses, longer exposure, and older age increase TD risk, necessitating careful monitoring.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Antipsychotic medications are crucial for managing psychiatric disorders.
- Tardive dyskinesia (TD) is a potential long-term side effect of antipsychotic treatment.
- Understanding the prevalence and risk factors for persistent TD is essential for patient safety.
Purpose of the Study:
- To determine the prevalence of probable and persistent tardive dyskinesia (TD) in patients on long-term antipsychotic therapy.
- To identify factors associated with the development of persistent TD.
Main Methods:
- A cohort of 353 patients on antipsychotics for ≥3 months was assessed.
- The Simpson Tardive Dyskinesia Rating Scale was used for diagnosis.
- Patients meeting criteria for probable TD were reassessed after 3 months to determine persistence.
Main Results:
- 40.2% of patients met criteria for probable tardive dyskinesia (TD).
- 25.5% of the total sample had persistent TD after 3 months.
- Age, total antipsychotic dosage, and duration of exposure were positively correlated with persistent TD.
Conclusions:
- A significant proportion of patients on long-term antipsychotics develop persistent tardive dyskinesia (TD).
- Risk factors for persistent TD include older age, higher antipsychotic dosage, and longer duration of treatment.
- Clinical monitoring for TD is crucial in patients receiving long-term antipsychotic therapy.
Related Concept Videos
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...